Myostatin Promotes Osteoclastogenesis by Regulating Ccdc50 Gene Expression and RANKL-Induced NF-κB and MAPK Pathways

Myostatin Promotes Osteoclastogenesis by Regulating Ccdc50 Gene Expression and RANKL-Induced NF-κB and MAPK Pathways

Myostatin is a crucial cytokine that is widely present in skeletal muscle and that negatively regulates the growth and development of muscle cells. Recent research has shown that myostatin might play an essential role in bone metabolism. In RAW264.7 cells and bone marrow monocytes (BMMCs), myostatin...

Full description

Bibliographic Details
Main Authors:	Xin Zhi, Qian Chen, Shaojun Song, Zhengrong Gu, Wenqiang Wei, Huiwen Chen, Xiao Chen, Weizong Weng, Qirong Zhou, Jin Cui, Liehu Cao
Format:	Article
Language:	English
Published:	Frontiers Media S.A. 2020-11-01
Series:	Frontiers in Pharmacology
Subjects:	osteoclastogenesis myostatin Ccdc50 Receptor activator of NF-κB ligand NF-κB
Online Access:	https://www.frontiersin.org/articles/10.3389/fphar.2020.565163/full

Similar Items

Deacylcynaropicrin Inhibits RANKL-Induced Osteoclastogenesis by Inhibiting NF-κB and MAPK and Promoting M2 Polarization of Macrophages
by: Zhikun Li, et al.
Published: (2019-06-01)

Berbamine inhibits RANKL- and M-CSF-mediated osteoclastogenesis and alleviates ovariectomy-induced bone loss
by: Guobin Qi, et al.
Published: (2022-11-01)

Pristimerin Suppresses RANKL-Induced Osteoclastogenesis and Ameliorates Ovariectomy-Induced Bone Loss
by: Dahu Qi, et al.
Published: (2021-01-01)

Specnuezhenide suppresses diabetes-induced bone loss by inhibiting RANKL-induced osteoclastogenesis
by: Ye Xiaoshuang, et al.
Published: (2022-08-01)

Niloticin inhibits osteoclastogenesis by blocking RANKL–RANK interaction and suppressing the AKT, MAPK, and NF-κB signaling pathways
by: Huanhuan Xu, et al.
Published: (2022-05-01)

Agelasine D Suppresses RANKL-Induced Osteoclastogenesis via Down-Regulation of c-Fos, NFATc1 and NF-κB
by: Moo Rim Kang, et al.
Published: (2014-11-01)

Thiaplakortone B attenuates RANKL‐induced NF‐κB and MAPK signaling and dampens OVX‐induced bone loss in mice
by: Qingqing Wang, et al.
Published: (2022-10-01)

Aspirin prevents estrogen deficiency-induced bone loss by inhibiting osteoclastogenesis and promoting osteogenesis
by: Yongyun Chang, et al.
Published: (2023-03-01)

Isopsoralen suppresses receptor activator of nuclear factor kappa-β ligand-induced osteoclastogenesis by inhibiting the NF-κB signaling
by: Wanda Zhan, et al.
Published: (2023-01-01)

Juglanin Inhibits Osteoclastogenesis in Ovariectomized Mice via the Suppression of NF-κB Signaling Pathways
by: Fangxue Zhang, et al.
Published: (2021-01-01)

Sesamolin Protects Mice From Ovariectomized Bone Loss by Inhibiting Osteoclastogenesis and RANKL-Mediated NF-κB and MAPK Signaling Pathways
by: Xue Yang, et al.
Published: (2021-06-01)

DANCR Mediates the Rescuing Effects of Sesamin on Postmenopausal Osteoporosis Treatment via Orchestrating Osteogenesis and Osteoclastogenesis
by: Zhengmeng Yang, et al.
Published: (2021-12-01)

Downregulation of miR-21 gene expression by CRE-Ter to modulate osteoclastogenesis: De Novo mechanism
by: Yutthana Pengjam, et al.
Published: (2021-07-01)

Dehydromiltirone inhibits osteoclast differentiation in RAW264.7 and bone marrow macrophages by modulating MAPK and NF-κB activity
by: Wei Deng, et al.
Published: (2022-09-01)

Inhibitory effects of ChondroT and its constituent herbs on RANKL-induced osteoclastogenesis
by: Rui Hong Guo, et al.
Published: (2019-11-01)

Aikeqing, a kidney- and spleen-tonifying compound Chinese medicine granule, prevented ovariectomy-induced bone loss in rats via the suppression of osteoclastogenesis
by: Zhi-Wen Liu, et al.
Published: (2023-10-01)

Mepazine Inhibits RANK-Induced Osteoclastogenesis Independent of Its MALT1 Inhibitory Function
by: Laura Meloni, et al.
Published: (2018-11-01)

Curcuminoid (CRE-Ter)/Liposome as delivery platform for anti-osteoclastogenesis via NF-κB/ERK pathways in RANKL-induced RAW 264.7 cells through PLA foams
by: Yutthana Pengjam, et al.
Published: (2021-09-01)

Inhibition of Lipopolysaccharide-Induced Inflammatory Bone Loss by Saikosaponin D is Associated with Regulation of the RANKL/RANK Pathway
by: Wu X, et al.
Published: (2021-11-01)

Peiminine Suppresses RANKL-Induced Osteoclastogenesis by Inhibiting the NFATc1, ERK, and NF-κB Signaling Pathways
by: Mengbo Zhu, et al.
Published: (2021-09-01)

Ginsenoside compound-K attenuates OVX-induced osteoporosis via the suppression of RANKL-induced osteoclastogenesis and oxidative stress
by: Lingli Ding, et al.
Published: (2023-11-01)

Dehydroxymethylepoxyquinomicin, a novel nuclear factor-κB inhibitor, prevents the development of cyclosporine A nephrotoxicity in a rat model
by: Shinya Morita, et al.
Published: (2020-08-01)

Effects of Taxifolin on Osteoclastogenesis in vitro and in vivo
by: Cong Cai, et al.
Published: (2018-11-01)

Traditional Chinese decoction Si Zhi Wan attenuates ovariectomy (OVX)-induced bone loss by inhibiting osteoclastogenesis and promoting apoptosis of mature osteoclasts
by: Qingman He, et al.
Published: (2022-09-01)

20(S)-Protopanaxadiol Inhibits Titanium Particle-Induced Inflammatory Osteolysis and RANKL-Mediated Osteoclastogenesis via MAPK and NF-κB Signaling Pathways
by: Chenhao Pan, et al.
Published: (2019-01-01)

Stabilization of CCDC102B by Loss of RACK1 Through the CMA Pathway Promotes Breast Cancer Metastasis via Activation of the NF-κB Pathway
by: Jing Si, et al.
Published: (2022-07-01)

Corydalis Saxicola Bunting Total Alkaloids Attenuate Walker 256-Induced Bone Pain and Osteoclastogenesis by Suppressing RANKL-Induced NF-κB and c-Fos/NFATc1 Pathways in Rats
by: Linjie Ju, et al.
Published: (2021-01-01)

The preliminary study suggests an association between NF-ĸB pathway activation and increased plasma 20S proteasome activity in intracranial aneurysm patients
by: Joanna Kamińska, et al.
Published: (2024-02-01)

Tyloxapol inhibits RANKL-stimulated osteoclastogenesis and ovariectomized-induced bone loss by restraining NF-κB and MAPK activation
by: Wen Guo, et al.
Published: (2021-05-01)

Progress and Prospects of Non-Canonical NF-κB Signaling Pathway in the Regulation of Liver Diseases
by: Li Tao, et al.
Published: (2022-07-01)

Baicalin Relieves LPS-Induced Lung Inflammation via the NF-κB and MAPK Pathways
by: Bingyu Shen, et al.
Published: (2023-02-01)

Suppression of NF-κB Activity: A Viral Immune Evasion Mechanism
by: Liyao Deng, et al.
Published: (2018-08-01)

Pristimerin Protects Against OVX-Mediated Bone Loss by Attenuating Osteoclast Formation and Activity via Inhibition of RANKL-Mediated Activation of NF-κB and ERK Signaling Pathways
by: Li X, et al.
Published: (2021-01-01)

NF-κB and Its Regulators During Pregnancy
by: Fernando Gómez-Chávez, et al.
Published: (2021-05-01)

At the crossroads of SUMO and NF-κB
by: Schmidt Christian, et al.
Published: (2003-11-01)

Tussilagone Inhibits Osteoclastogenesis and Periprosthetic Osteolysis by Suppressing the NF-κB and P38 MAPK Signaling Pathways
by: Xuantao Hu, et al.
Published: (2020-04-01)

Magnoflorine Suppresses MAPK and NF-κB Signaling to Prevent Inflammatory Osteolysis Induced by Titanium Particles In Vivo and Osteoclastogenesis via RANKL In Vitro
by: Zhenyu Sun, et al.
Published: (2020-04-01)

Vindoline Attenuates Osteoarthritis Progression Through Suppressing the NF-κB and ERK Pathways in Both Chondrocytes and Subchondral Osteoclasts
by: Meisong Zhu, et al.
Published: (2022-01-01)

Isosinensetin alleviates estrogen deficiency-induced osteoporosis via suppressing ROS-mediated NF-κB/MAPK signaling pathways
by: Yiwu Qin, et al.
Published: (2023-04-01)

Flavopiridol Protects Bone Tissue by Attenuating RANKL Induced Osteoclast Formation
by: Zi’ang Hu, et al.
Published: (2018-05-01)